Navigation Links
Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
Date:1/15/2008

REINACH, Switzerland, January 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it has received authorisation from the U.S. Food and Drug Administration (FDA) to conduct a Phase II 'intravenous-to-oral' switch trial with iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with intravenous (IV) vancomycin in the treatment of cSSSI. The primary endpoint will be the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcomes as well as safety and tolerability.

This Phase II trial is designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI will receive IV vancomycin for the first two days of treatment and will then be randomised to either continue to receive IV vancomycin or be switched to oral iclaprim for eight additional days. A total of 60 patients will be randomised for this study.

Iclaprim is also being developed as an intravenous formulation for two indications: cSSSI and nosocomial pneumonia. In the cSSSI indication the drug candidate has completed its pivotal Phase III trial programme and is currently in an NDA-filing process. In the nosocomial pneumonia indication, the drug candidate is currently in Phase II.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Among the hospital anti-MRSA drugs that are currently in filing or late-stage development, only iclaprim shows good oral bioavailability and consequently offers the potential for intravenous-to- oral switch therapy. We believe that intravenous-to-oral switch therapy is important as it could provide a means to enhance patient comfort, reduce risk of spread of infection and reduce hospital-associated healthcare costs. In parallel with this Phase II trial, we are continuing our work on th
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida-Supported CME Symposium Available Online
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Arpida Presents Preclinical Data on AR-2474 at ICAAC
4. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
5. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
6. Arpida Interim Results for six Months to 30 June 2007
7. Genta Receives Notice of Non-Compliance With NASDAQ Rule
8. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
9. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
10. EaglePicher Technologies Receives Battery Power Products and Technologys First Annual Innova Award
11. Aida Receives Chinese Government Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
(Date:1/14/2014)... January 14, 2014 Independent publisher Bitingduck ... and Montreal, Canada, has big ideas for 2014 in ... press's goals are to produce high-quality, low-cost, DRM-free ebooks ... local businesses. , The first major development will ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... March 20, 2012 /PRNewswire-iReach/ -- Systems Alliance, ... build, assess and optimize online properties, today announced it ... The Living Legacy Foundation . The non-profit organization facilitates ... for transplantation and research in Maryland with the exception ...
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... 2012 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... fight Human Immunodeficiency Virus (HIV) infections, announced today ... certain institutional investors, pursuant to which the Company ... A convertible preferred stock at an aggregate purchase ...
Cached Biology Technology:Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland 2Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland 3Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2GeoVax Announces Private Placement of $2.2 Million 2GeoVax Announces Private Placement of $2.2 Million 3GeoVax Announces Private Placement of $2.2 Million 4
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
(Date:7/9/2014)... The U.S. may be on the verge of an economy ... burns cleaner than coal and is undergoing a production boom. ... globally, but recent research is casting serious doubts over just ... Chemical & Engineering News (C&EN), the weekly news magazine ... Johnson, a senior correspondent at C&EN, explains that when burned ...
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... -- The Society of Environmental Toxicology and Chemistry will present ... its 33rd Annual Meeting, November 11 at the Long Beach ... the Rosenstiel School of Marine & Atmospheric Science of the ... to the understanding of fate and effects of metals in ...
... Four young scientists have received postdoctoral fellowships from the ... program, they conduct research with the eventual aim of ... receiving mentorship from a faculty member at their home ... seven research teams. This allows them to interact with ...
... 2012  Verinata Health, Inc., a privately-held company dedicated to ... at the 62 nd Annual Meeting of the ... being held in San Francisco, California. (Logo: ... offers pregnant women access to a blood test that ...
Cached Biology News:SETAC announces Chris Lee Award for metals research winner, Kevin Brix 2Space research institute awards postdoctoral fellowships to 4 scientists 2Verinata Health Announces New Findings At The American Society Of Human Genetics 2
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Multipeptide Kit, designed for use with ... variety of amyloid peptides more straightforward ... Clinical neuroscience proteomics applications - Monitor ... Correlate beta-amyloid peptide levels with disease ...
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: